The endoconnabinoid system in ageing: A new target for drug development

A. Paradisi, S. Oddi, M. Maccarrone

Research output: Contribution to journalArticlepeer-review


Endocannabinoids are a new class of lipids, which include amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol are the main endogenous agonists of cannabinoid receptors able to mimic several pharmacological effects of D9-tetrahydrocannabinol, the active principle of Cannabis sativa preparations like hashish and marijuana. AEA is released "on demand" from membrane lipids, and its activity at the receptors is limited by cellular uptake followed by intracellular hydrolysis. Together with AEA and congeners, the proteins which bind, synthesize, transport and hydrolyze AEA form the "endocannabinoid system". Endogenous cannabinoids are present in the central nervous system and in peripheral tissues, suggesting a physiological role as broad spectrum modulators. This review summarizes the main features of the endocannabinoid system, and the latest advances on its involvement in ageing of central and peripheral cells. In addition, the therapeutic potential of recently developed drugs able to modulate the endocannabinoid tone for the treatment of ageing and age-related human pathologies will be reviewed.

Original languageEnglish
Pages (from-to)1539-1552
Number of pages14
JournalCurrent Drug Targets
Issue number11
Publication statusPublished - Nov 2006


  • Ageing
  • Cannabinoids
  • Excitotoxicity
  • Immune system
  • Inflammation
  • Nervous system
  • Neurodegenerative disorders
  • Osteoarthritis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science


Dive into the research topics of 'The endoconnabinoid system in ageing: A new target for drug development'. Together they form a unique fingerprint.

Cite this